News Conference News ESC 2025 MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide Caitlin E. Cox August 30, 2025
News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Conference News TCT 2023 SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC Yael L. Maxwell October 30, 2023
News Conference News TVT 2023 ‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients Michael O'Riordan June 09, 2023
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ESC 2020 EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class Michael O'Riordan August 29, 2020
News Conference News CRT 2018 Early Results for Dock-Plus-Valve Approach Promising in Transcatheter Mitral Valve Replacement Shelley Wood March 07, 2018